Tevogen Bio [TVGN] - Last Close: $2.62
Yesterday, Tevogen Bio announced the appointment of Wall Street veteran Japan Shah as head of investor relations and corporate development.
The news broke in the premarket, and TVGN fell 11% in the trading session immediately following the announcement.
However, TVGN is rebounding today. It’s a top mover with a 98.0% gain on more than 5.5 million shares traded.
My Take: TVGN is coming off a long losing streak, but this rally could indicate the declines have been overdone. It could be worth monitoring if it can continue this upswing.
Reliance Global [RELI] - Last Close: $0.37
This morning, EF Hutton analyst Tim Moore assume coverage on Reliance Global with a “buy” rating and a $7 price target.
RELI is surging in response to the analyst upgrade. It’s up 73.6% on upwards of 15 million shares traded.
My Take: RELI saw a big volume spike yesterday, so this move could be the result of a natural correction, in addition to the upgrade catalyst.
Candel Therapeutics [CADL] - Last Close: $1.68
This tiny biotech is rallying after publishing positive interim data from a Phase 2 trial of CAN-2409 in non-metastatic pancreatic cancer patients.
Candel said the drug showed notable improvements in overall survivability and was generally safe and well tolerated among patients.
CADL is up 36.3%, and more than 2.5 million shares have been traded in the premarket thus far.
My Take: This move is on pace to put CADL above a key resistance point, and it could find new support at this level if it can hold on.
Hub Cyber Security [HUBC] - Last Close: $0.719
Hub Cyber just announced its acquisition of Qpoint Technologies in a move that will advance its plans for a “secured data fabric ecosystem.”
Upon closing, Hub now owns 100% of Point, a company with expertise in software engineering, testing, cybersecurity, ICT, web, mobile, and more.
Financial details weren’t disclosed in the initial press release, but HUBC is up 28.2% on nearly 5 million shares traded in response to the news.
My Take: This rally seems to be fueled by hype. I am not confident HUBC will hold onto these gains, given its recent performance.